Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth ...

Center at UCSF is pioneering the development of potent drug candidates aimed at preventing future coronavirus pandemics.

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

With volatility taking center stage since the beginning of the year, investing in the stock market isn’t as easy as it was.

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Paxlovid, an antiviral medication, was found ineffective in alleviating long COVID symptoms in a decentralized clinical trial involving 100 participants across the United States.